The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Response of Retinoblastoma With Vitreous Tumor Seeding to Adenovirus-Mediated Delivery of Thymidine Kinase Followed by Ganciclovir
Abstract
Purpose: To evaluate the feasibility and safety of adenovirus-mediated gene therapy as a treatment for tumor seeds in the vitreous of children with retinoblastoma. Patients and Methods: An Institutional Biosafety Committee–, Institutional Review Board–, Recombinant DNA Advisory Committee–, and US Food and Drug Administration–approved phase I study used intrapatient dose escalation of adenoviral vector containing a herpes simplex thymidine kinase gene (AdV-TK) followed by systemic administration of ganciclovir to treat bilateral retinoblastoma with vitreous tumor seeding refractory to standard therapies. Vitreous tumor seeds were treated by intravitreous injection of AdV-TK adjacent to disease sites. Each injection was followed by ganciclovir delivered intravenously every 12 hours for 7 days. Results: Eight patients with vitreous tumor seeds were enrolled. One patient who was treated with 10 8 viral particles (vp) had resolution of the tumor seeds around the injection site. The seven patients who were treated with doses ≥ 10 10 vp had resolution of their vitreous tumor seeds documented by fundoscopy. Toxicity included mild inflammation at 10 10 vp and moderate inflammation, corneal edema, and increased intraocular pressure at 10 11 vp. One patient was free of active vitreous tumor seeds 38 months after therapy. There has been no evidence of extraocular spread of tumor along the needle tract in any patient. Conclusion: AdV-TK followed by ganciclovir can be administered safely to children with retinoblastoma. Suicide gene therapy may contribute to the treatment of children with retinoblastoma tumor seeds in the vitreous, a resistant complication of retinoblastoma.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The retinoblastoma cohort consisted of eight patients, five of whom developed ocular inflammation even though there was no measurable humoral or cellular immune response [65].”
From Immune responses to gene editing by viral and non-viral delivery vectors used in retinal gene therapy (2022) · cites this paper as [65]
Citations
Cites
Mutation and cancer: statistical study of retinoblastoma
Knudson, A. G. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.4.820 · Cited by 7,612
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
Chen, S. H., Shine, H. D., Goodman, J. C., Grossman, R. G., & Woo, S. L. C. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.3054 · Cited by 476
Chemotherapy Plus Local Treatment in the Management of Intraocular Retinoblastoma
Murphree, A. L. (1996) · Archives of Ophthalmology · doi:10.1001/archopht.1996.01100140548005 · Cited by 471
Chemotherapy With Focal Therapy Can Cure Intraocular Retinoblastoma Without Radiotherapy
Gallie, B. L. (1996) · Archives of Ophthalmology · doi:10.1001/archopht.1996.01100140521001 · Cited by 412
Chemoreduction in the Initial Management of Intraocular Retinoblastoma
Shields, C. L. (1996) · Archives of Ophthalmology · doi:10.1001/archopht.1996.01100140530002 · Cited by 358
In Situ Gene Therapy for Adenocarcinoma of the Prostate: A Phase I Clinical Trial
Herman, J. R., Adler, H. L., Aguilar-Córdova, E., Rojas‐Martínez, A., Woo, S. L. C., Timme, T. L., Wheeler, T. M., Thompson, T. C., & Scardino, P. T. (1999) · Human Gene Therapy · doi:10.1089/10430349950018229 · Cited by 301
Trask, T., Trask, R. P., Aguilar-Córdova, E., Shine, H. D., Wyde, P. R., Goodman, J. C., Hamilton, W. J., Rojas‐Martínez, A., Chen, S., Woo, S. L. C., et al. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0030 · Cited by 262
Aa, E., Saavedra, A., Zhang, H., Kucharczuk, J. C., Dc, S., Fishman, G. I., Km, A., Kaiser, L. R., & Albelda, S. (1996) · PubMed · Cited by 259
Incidence of Second Neoplasms in Patients with Bilateral Retinoblastoma
Roarty, J. D., McLean, I. W., & Zimmerman, L. E. (1988) · Ophthalmology · doi:10.1016/s0161-6420(88)32971-4 · Cited by 254
Cited by
Sorted by citations
Gaudana, R., Ananthula, H. K., Parenky, A., & Mitra, A. K. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9183-3 · Cited by 1,406
Prodrugs for improving tumor targetability and efficiency
Mahato, R., Tai, W., & Cheng, K. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.02.002 · Cited by 355
Campochiaro, P. A., Nguyen, Q. D., Shah, S. M., Klein, M. L., Holz, E., Frank, R. N., Saperstein, D. A., Gupta, A., Stout, J. T., Macko, J., et al. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.167 · Cited by 343
Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy
Cideciyan, A. V. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.04.002 · Cited by 256
“Although there have been previous attempts of gene therapy in human ocular disease (Campochiaro et al., 2006; Chevez-Barrios et al., 2005), recent RPE65 gene therapy trials © 2010 Elsevier Ltd.”
ResultMunier, F. L., Soliman, S. E., Moulin, A., Gaillard, M., Balmer, A., & Popovic, M. B. (2012) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2011-301016 · Cited by 223
Metadata
- Authors
- Chévez-Barrios, P., Chintagumpala, M., Mieler, W., Paysse, E., Boniuk, M., Kozinetz, C., Hurwitz, M. Y., & Hurwitz, R. L.
- Affiliations
- From the Departments of Pathology, Ophthalmology, and Pediatrics, Texas Children's Cancer Center; the Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital; and the Methodist Hospital, Houston, TX
- Houston Methodist (US)
- Venue
- Journal of Clinical Oncology
- Published
- 2005-11-01
- Volume
- 23
- Issue
- 31
- Pages
- 7927-7935
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2166510225
- Cited by
- 143
- References
- 32
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 4 · 2022: 7 · 2021: 5 · 2020: 4 · 2019: 3 · 2018: 1 · 2017: 9 · 2016: 4 · 2015: 10 · 2014: 7 · 2013: 5 · 2012: 10
- FWCI
- 8.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (R21CA097762, CA97762)
- Topics
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Keywords
- retinoblastoma, adenoviral vector, herpes simplex thymidine kinase, ganciclovir, suicide gene therapy, gene therapy toxicity, pediatric retinoblastoma, intravitreal injection, dose escalation
- MeSH terms
- Adenoviruses, Human, Antiviral Agents, Child, Combined Modality Therapy, Feasibility Studies, Genetic Vectors, Humans, Neoplasm Recurrence, Local, Neoplasm Seeding, Retinoblastoma, Thymidine Kinase, Vitreous Body, Genetic Therapy, Ganciclovir, Gene Transfer Techniques, Retinal Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
